{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1047.376","meta":{"versionId":"17","lastUpdated":"2016-12-27T01:00:03.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.376","version":"20161227","name":"Moderate Emetic Risk Cancer MEdicine interferon alfa 2b","status":"active","date":"2016-12-27T01:00:03-05:00","publisher":"Oncology Nursing Society Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"5880","display":"Interferon Alfa-2b"}]}]},"expansion":{"identifier":"urn:uuid:a9aa6904-89e2-450b-9d70-c3a59e661d02","timestamp":"2022-06-10T09:50:24-04:00","total":1,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"5880","display":"interferon alfa-2b"}]}}